2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urologic Diseases
1
Nephritis
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Kidney Diseases
1
Immune System Diseases
1
Heart Failure
1
Glomerulonephritis, IGA
1
Glomerulonephritis
1
Cardiomyopathies
1
Autoimmune Diseases
1
Interventions
Sunitinib
4
avelumab
2
Nutrition Assessment
2
Blood Specimen Collection
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Specimen Handling
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Diseases
×
Valsartan
×
Clear all
NCT02765594
2017-09-20
HCQIgAN
Peking Union Medical College Hospital
Phase 4
Unknown
98 enrolled